Tigwa Davis, PhD

Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Care Systems

Background: Treatment resistant depression (TRD) is burdensome to health systems. Earlier identification of at-risk patients may reduce clinical inertia and improve outcomes.

Jacqueline Pesa , PhD, MPH;

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Tigwa Davis , PhD;

Sara Heverly-Fitt , PhD;

John Verbanac , PhD;

Wing Chow , PharmD, MPH;

11/22/2019

Descriptive Patterns Emerging From Initial Antidepressant Treatment Episodes in Patients with Treatment-Resistant Depression

Background: TRD leads to excess healthcare costs and burden of illness. Early patterns of antidepressant use may signify patients at high-risk for TRD. Methods: Eligible patients with ma...

John Verbanac , PhD;

Wing Chow , PharmD, MPH;

Jacqueline Pesa , PhD, MPH;

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Tigwa Davis , PhD;

Sara Heverly-Fitt , PhD;

11/22/2019

A Comparison of Barriers and Drivers Between Prescribing and Non-Prescribing Psychiatric Care Providers Regarding Use of Digital Medication Adherence Platforms

Background: Tracking medication adherence through an ingestible event monitoring (IEM) sensor could benefit seriously mentally ill patients (SMI). Psychiatric providers may be reluctant t...

Jennifer Clerie , BS ;

Charles Ruetsch , PhD;

Heidi Waters , PhD, MBA;

Tigwa Davis , PhD;

Dawn Velligan , PhD;

Delbert Robinson , MD;

Chris Jaeger , MD, MBA;

William Carpenter , MD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

11/22/2019

Barriers and Drivers of Adopting a Digital Medication Adherence Technology: Understanding the Factor Analysis Results

Background: A new digital medicine technology combining an ingestible event monitoring (IEM) sensor with an oral antipsychotic to track ingestion and adherence may be beneficial. However,...

William Carpenter , MD;

Joshua Liberman , PhD;

Felicia Forma , BSc;

Charles Ruetsch , PhD;

Jennifer Clerie , BS ;

Tigwa Davis , PhD;

Heidi Waters , PhD, MBA;

Dawn Velligan , PhD;

Delbert Robinson , MD;

Chris Jaeger , MD, MBA;

11/22/2019

Early Assessment of Ustekinumab for Crohn’s Disease: A Chart Review

BACKGROUND: Ustekinumab was approved by the FDA in September 2016 for the treatment of patients with moderate-to-severe Crohn’s Disease (CD). Little is published about either the health a...

Antuane Allen ;

Jennifer Clerie , BS ;

Charles Ruetsch , PhD;

Tigwa Davis , PhD;

Erik Muser ;

James Izanec ;

Camilo Obando ;

11/20/2018